Hyperlipidemia. Intern Immersion Block 2015

Similar documents
How would you manage Ms. Gold

Disclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?

Placebo-Controlled Statin Trials Prevention Of CVD in Women"

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Placebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES

Prevention of Heart Disease: The New Guidelines

No relevant financial relationships

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Treating Lipids for Prevention of CAD in Women: Matching Therapy to Risk

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

Disclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Pharmaceutical Help to Control Cholesterol

4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for

Placebo-Controlled Statin Trials

Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

What do the guidelines say about combination therapy?

Lipids & Hypertension Update

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

New Guidelines in Dyslipidemia Management

No relevant financial relationships

New Guidelines in Dyslipidemia Management

Review of guidelines for management of dyslipidemia in diabetic patients

Learning Objectives. Patient Case

Hyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

ATP IV: Predicting Guideline Updates

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

Decline in CV-Mortality

Lipid Panel Management Refresher Course for the Family Physician

New Cholesterol Guidelines What the LDL are we supposed to do now?!

2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines

Lipid Management 2013 Statin Benefit Groups

Dyslipidemia: Lots of Good Evidence, Less Good Interpretation.

Treatment of Cholesterol in 2018: Time to Level Up. Most Important Slide. Three Things Learned that Will be Applied

Dyslipedemia New Guidelines

Preventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk

Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway

4/24/15. AHA/ACC 2013 Guideline Key Points

Cholesterol Management Roy Gandolfi, MD

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

MOLINA HEALTHCARE OF CALIFORNIA

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

CVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure

Sanger Heart & Vascular Institute Symposium 2015

Introduction. Objective. Critical Questions Addressed

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.

2013 ACC/AHA Cholesterol Guidelines JULIE HAMMOND, D.O. PGY-2 MATTHEW PAOLI, D.O. PGY-2

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Joshua Shepherd PA-C, MMS, MT (ASCP)

2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004

How to Handle Statin Intolerance in the High Risk Patient

2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.

Young high risk patients the role of statins Dr. Mohamed Jeilan

4 th and Goal To Go How Low Should We Go? :

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

Lipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology

9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

Treating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC

Update on Atherosclerosis Treatment and Prevention

Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?

Conflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?

1. Which one of the following patients does not need to be screened for hyperlipidemia:

Calculating RR, ARR, NNT

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Acute Coronary Syndromes (ACS)

The Clinical Debates

Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center

Landmark Clinical Trials.

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines

Eyes on Korean Data: Lipid Management in Korean DM Patients

What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?

Primary Prevention of Cardiovascular Disease (CVD) Events with Statins. 1 Primary Prevention of Cardiovascular Disease (CVD) Events with Statins

STATIN UTILIZATION MANAGEMENT CRITERIA

HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016

Review current guideline recommendations for lipid-lowering therapy

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Joslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia

Update on Hyperlipidemia Guidelines

Lipids What s new? Meera Jain, MD Providence Portland Medical Center

Diabetic Dyslipidemia

The Pharmacists Role in Lipid Management

PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN

Lipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute

Should we base treatment decisions on short-term or lifetime CVD risk? Rod Jackson University of Auckland New Zealand

Top 5 (Topics) Papers In GIM Rocky Mountain ACP Internal Medicine Meeting Raj Padwal November 13, 2008

Statins and PCSK9 inhibitors for stroke prevention

Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease

Transcription:

Hyperlipidemia Intern Immersion Block 2015 Christopher Wong, MD Division of General Internal Medicine University of Washington cjwong@u.washington.edu

Welcome!

Disclosures: royalties from book sales (not relevant to this talk) (all of which I donate)

There are new guidelines!!!

There are new guidelines!!! Not etched in stone...

There are new guidelines!!! Not etched in stone... Just because they are new does not mean they are right

There are new guidelines!!! Not etched in stone... Just because they are new does not mean they are right But the the old ones were not necessarily right either

There are new guidelines!!! What are we going to talk about: Old guidelines New guidelines Common questions

The old way

Case: the old way A 60 year old man with hypertension and diabetes has an LDL of 180, HDL 35 and total cholesterol 245. What is this patient s LDL goal? A Less than 130 B Less than 100 C Less than 70 D Less than zero

ATPIII Age: Male 45 / Female 55 Family History: premature CHD Smoking Hypertension HDL <40 Negative risk factor: HDL 60+ RISK RFs 10 YEAR CATEGORY RISK LDL GOAL LOW 0-1 <10% <160 > 190 MODERATE 2+ <10% <130 >160 Meds upfront MODERAT ELY HIGH RISK 2+ 10-20% <130 >130 HIGH CHD or Equivalent >20% <100 Op#onal <70 >130

Case: the old way A 60 year old man with hypertension and diabetes has an LDL of 180, HDL 35 and total cholesterol 245. What is this patient s LDL goal? A Less than 130 B Less than 100 C Less than 70 D Less than zero

Case: the old way A 60 year old man with hypertension and diabetes has an LDL of 180, HDL 35 and total cholesterol 245. What is this patient s LDL goal? A Less than 130 B Less than 100 C Less than 70 D Less than zero

ATP III: Treatment Meds: Statins Bile acid sequestrants (!) TLC Diet Reduce saturated fat and cholesterol intake More fiber and sterols/stanols Exercise Lose weight

2002 Adult Treatment Panel III (ATP-III) 2004 Update NCEP National Cholesterol Educational Program

2002 Adult Treatment Panel III (ATP-III) 2004 Update NCEP National Cholesterol Educational Program 2004 George W Abu Ghraib Tony Blair Libya Red Sox 2013 finally... Before the era of: You Tube Katrina iphone Tsunami Barack Obama Economic crisis Affordable Care Act College (for some of you)

It wasn t a problem just because it was old

2 patients with diabetes 60 year old woman Diabetes LDL 110 LDL 90 60 year old woman Diabetes LDL 160 LDL 90

2 patients with diabetes 60 year old woman Diabetes LDL 110 LDL 90 60 year old woman Diabetes LDL 160 LDL 90 Both are treated to LDL goals. Which patient achieved greater risk reduction?

2 patients with diabetes 60 year old woman Diabetes LDL 110 LDL 90 60 year old woman Diabetes LDL 160 LDL 105

2 patients with diabetes 60 year old woman Diabetes LDL 110 LDL 90 60 year old woman Diabetes LDL 160 LDL 105 Only one patient achieved LDL goal < 100. Which achieved greater risk reduction?

Problems Treating to LDL goals: How were studies of cholesterol lowering done?

Almost all trials with clinical endpoints Fixed dose of stasn versus Placebo or One stasn versus Another stasn

The mechanics of cholesterol lowering: what do (did) we actually do? Screen lipids à if high, start lifestyle changes Recheck lipids à if still high, start medication Recheck lipids à if still high, increase medication Recheck lipids à if stable, recheck next year Patient has new RF à change LDL goal, change or increase meds à recheck lipids

Problems with LDL strategy No studies have ever been done screening and treating to LDL targets Statins, which have the strongest evidence, reduce risk over wide range of lipid levels Hayward & Krumholz. Circ Cardiovasc Qual Outcomes 2012; 5:2-5

55M Nonsmoker SBP 120 HDL 55 CRP 5 (-) family history LDL 190 55M Smoker SBP 140 HDL 25 CRP 5 (+) family history LDL 90 5 yr risk ~ 3% NNT = 83 5 yr risk ~ 8% NNT = 31 Hayward & Krumholz. Circ Cardiovasc Qual Outcomes 2012; 5:2-5

New guidelines

Remember this: How much risk? How much treatment?

Remember this: How much risk? How much treatment?

Remember this: How much risk? How much treatment?

Remember this: How much risk? How much treatment?

Remember this: How much risk? How much treatment?

Remember this: How much risk? How 84 pages! much treatment?

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Primary or Secondary prevention?

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Primary or Secondary prevention?

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Primary or Secondary prevention? Risk? High Moderate Low

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Primary or Secondary prevention? Old guidelines? Risk? High Moderate Low

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Primary or Secondary prevention? Risk? High Moderate Low Old guidelines? Titrate to LDL

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. Treatment: Statin Risk category: clinical atherosclerotic disease New guidelines Age 75: high intensity (or moderate if cannot tolerate) Age > 75: moderate intensity

Risk category: clinical atherosclerotic disease Cerebrovascular: stroke, TIA PAD: peripheral arterial disease CAD: -acute coronary syndromes -history of MI -stable or unstable angina Revascularization: coronary or other arterial revascularization

What is high intensity?

What is high intensity? Drug High Intensity (mg) Moderate Intensity (mg) AtorvastaSn 80 (40?) 10 (20?) Low Intensity (mg) RosuvastaSn 20 10 SimvastaSn 20-40 10 (?) PravastaSn 40 10-20 LovastaSn 40 20

What is high intensity? Drug High Intensity (mg) Moderate Intensity (mg) AtorvastaSn 80 (40?) 10 (20?) Low Intensity (mg) RosuvastaSn 20 10 SimvastaSn 20-40 10 (?) PravastaSn 40 10-20 LovastaSn 40 20

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Primary or Secondary prevention? Risk: High Moderate Low

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Primary or Secondary prevention? Old guidelines? Risk: High Moderate Low

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Primary or Secondary prevention? Old guidelines? Risk: High Moderate Low Same as case #1 ischemic equivalent

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Risk category: Diabetes Type 1 or 2 Age 40-75 Treatment: Moderate intensity statin. New guidelines If risk 7.5%, then high-intensity statin

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Risk category: Diabetes Type 1 or 2 Age 40-75 New guidelines Treatment: Moderate intensity statin. atorvastatin 10-20 simvastatin 20-40 If risk 7.5%, then high-intensity statin atorvastatin 40-80 rosuvastatin 20

How to estimate risk?

How to estimate risk? Framingham, MA The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again. http://www.maliving.com/towns/framingham/ http://familysearch.org/learn/wiki/en/framingham,_massachusetts

Framingham

Framingham MI / death Simple Easy to use Easily found data

Framingham MI / death Simple Not for those Easy to use with CAD or Easily found data DM!

How to estimate risk? http://tools.cardiosource.org/ascvd-risk-estimator/

How to estimate risk? New guidelines: they made their own risk calculator http://tools.cardiosource.org/ascvd-risk-estimator/

How to estimate risk? New guidelines: they made their own risk calculator Data from Cholesterol Trialists Collaboration http://tools.cardiosource.org/ascvd-risk-estimator/

How to estimate risk? New guidelines: they made their own risk calculator Data from Cholesterol MI and stroke Trialists Collaboration http://tools.cardiosource.org/ascvd-risk-estimator/

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Non-smoker, TC 220 HDL 35, on BP meds, SBP 120. New guidelines: Treatment: Risk category: Diabetes Type 1 or 2 Age 40-75 Moderate intensity statin. atorvastatin 10-20 simvastatin 20-40 If risk 7.5%, then high-intensity statin

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Non-smoker, TC 220 HDL 35, on BP meds, SBP 120. New guidelines: Risk category: Diabetes Type 1 or 2 Age 40-75 Treatment: Moderate intensity statin. atorvastatin 10-20 simvastatin 20-40 If risk 7.5%, then high-intensity statin

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker.

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker. Primary or Secondary prevention? Risk: High Medium Low

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker. Primary or Secondary prevention? Risk: High Medium Low Old guidelines? 0-1 risk factor male > 45 LDL goal < 160 Meds at > 190 or fail lifestyle changes

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker. New guidelines

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker. 10 yr risk 7.5%: Moderate to high intensity statin New guidelines

New guidelines case 4 One more category to know: LDL 190 Considered high risk Consider evaluation for familial syndrome

New guidelines case 4 One more category to know: LDL 190 Considered high risk Consider evaluation for familial syndrome Treatment: High intensity statin Moderate if unable to tolerate

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Notes Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize

But wait not everyone is happy with the new guidelines

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize #1: not all evidence levels are the same Notes How long to do high intensity? Not much evidence for > 75 years old Slightly weaker level of evidence. High intensity b/c how far to go. Moderate intensity: strong level of evidence Higher intensity: weaker evidence (IIa / B) They consider this a I/ A rec.

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize #1: not all evidence levels are the same Notes How long to do high intensity? Not much evidence for > 75 years old Slightly weaker level of evidence. High intensity b/c how far to go. Moderate intensity: strong level of evidence Higher intensity: weaker evidence (IIa / B) They consider this a I/ A rec.

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize #1: not all evidence levels are the same Notes How long to do high intensity? Not much evidence for > 75 years old Slightly weaker level of evidence. High intensity b/c how far to go. Moderate intensity: strong level of evidence Higher intensity: weaker evidence (IIa / B) They consider this a I/ A rec.

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize #1: not all evidence levels are the same Notes How long to do high intensity? Not much evidence for > 75 years old Slightly weaker level of evidence. High intensity b/c how far to go. Moderate intensity: strong level of evidence Higher intensity: weaker evidence (IIa / B) They consider this a I/ A rec.

New guidelines: controversies #2: the risk calculator: at extremes performs weirdly #3: threshold for primary prevention 7.5%? Too low or too high? (Is there any number everyone would agree on?) this is a value/judgment call, not evidence #4: how long to do high intensity therapy? And finally, #5: some people don t think statins work at all for primary prevention

New guidelines: controversies #2: the risk calculator: at extremes performs weirdly #3: threshold for primary prevention 7.5%? Too low or too high? (Is there any number everyone would agree on?) this is a value/judgment call, not evidence #4: how long to do high intensity therapy? And finally, #5: some people don t think statins work at all for primary prevention

New guidelines: controversies #2: the risk calculator: at extremes performs weirdly #3: threshold for primary prevention 7.5%? Too low or too high? (Is there any number everyone would agree on?) this is a value/judgment call, not evidence #4: how long to do high intensity therapy? And finally, #5: some people don t think statins work at all for primary prevention

So what (in general) do I actually do?

Risk category Secondary preven#on Clinical No AtheroscleroTc Cardiovascular Disease Calculate risk? Treatment High intensity stasn Moderate if Age > 75 or cannot tolerate high intensity dosing Primary preven#on LDL 190 No High intensity stasn Moderate if cannot tolerate Notes Yes, but might step down after a few years More likely to use moderate Diabetes Yes 10 year risk < 7.5%: moderate intensity 7.5%: high intensity More likely to use moderate LDL < 190 no DM Yes 10 year risk 7.5%: moderate to high intensity < 7.5%: individualize More likely to use moderate

New guidelines case 1 60 year old man, MI last year, on aspirin, clopidogrel, lisinopril, metoprolol. Forgot to refill statin. High dose statin is reasonable why? Very high risk, just had an MI Risks of statin seem acceptable

New guidelines case 2 60 year old woman with diabetes, no heart attack etc. Non-smoker, TC 220 HDL 35, on BP meds, SBP 120. New guidelines: Risk category: Diabetes Type 1 or 2 Age 40-75 I d probably stick with moderate intensity (Heart Protection Study) atorvastatin 10-20 simvastatin 20-40 Increase if patient is wanting to lower risk further, accept some increased statin side effects. atorvastatin 40-80 rosuvastatin 20

New guidelines case 3 55 year old, regular guy. No CV disease or DM. No meds. TC 250 HDL 45 LDL 170. SBP 130. Nonsmoker. 10 yr risk 7.5%: Moderate to high intensity statin I d discuss risks and benefits. If he wants to take a pill to lower his risk, and is ok with possible side effects, then start a statin. Start with moderate dose.

What do other organizations advocate? VA guidelines (2014) -secondary prevention: mod-high dose statin -risk > 12%: mod dose statin -risk 6-12%: mod dose statin (shared dec) Risk < 6%: none NICE (2014) -QRISK2 score -Risk >10%: atorvastatin 20 mg -CVD: atorvastatin 80 mg USPSTF???

Common questions

When do I start screening?

When do I start screening? Old guidelines: all adults 20 years or older New guidelines: They don t really say, but the risk calculator starts at age 40.... USPSTF: Men 35, or younger if RFs Women if RFs. (reality: most would screen women 45) Younger pasents: if increased risk http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/section2c.html#lipid

What do I order? A. Fasting lipid panel B. Non-fasting lipid panel C. Total and HDL, fasting D. Total and HDL, non-fasting

Fasting vs non-fasting FasTng Non- fastng Total and HDL Lipid panel FasSng lipid panel preferred. Can screen for DM also Lower triglycerides (usually), more likely to be able to calculate an LDL Less convenient pasents may not return for a fassng test More opportunissc / convenient Does not affect total and HDL anyway May have high triglycerides and end up repeasng it fassng Total and HDL not affected by diet Risk calculator uses total and HDL USPSTF: total and HDL High LDL is a risk category in current guidelines FasSng lipid panel preferred. Cost?

Lipid panel vs total/hdl FasTng Non- fastng Total and HDL Lipid panel FasSng lipid panel preferred. Can screen for DM also Lower triglycerides (usually), more likely to be able to calculate an LDL Less convenient pasents may not return for a fassng test More opportunissc / convenient Does not affect total and HDL anyway May have high triglycerides and end up repeasng it fassng Total and HDL not affected by diet Risk calculator uses total and HDL USPSTF: total and HDL High LDL is a risk category in current guidelines FasSng lipid panel preferred. Cost?

Lipid panel vs total/hdl FasTng Non- fastng Total and HDL Lipid panel FasSng lipid panel preferred. Can screen for DM also Lower triglycerides (usually), more likely to be able to calculate an LDL Less convenient pasents may not return for a fassng test More opportunissc / convenient Does not affect total and HDL anyway Total and HDL not affected by diet Risk calculator uses total and HDL USPSTF: total and HDL à I generally order a lipid panel (not just total/hdl), May have high High LDL is a risk and triglycerides decide and with category the patient in current end up repeasng it guidelines on fassng fasting vs non-fasting FasSng lipid panel preferred. Cost?

What about lp(a) and all those other particles?

Panel or total/hdl? HDL total LDL Other stuff } all bad!

How often should I recheck the lipid panel?

Rechecking lipid panels Not everybody needs a yearly lipid panel! Not on treatment: every 4-6 years (age 40-75, without cardiovascular disease or DM, and with LDL 70-189)

Rechecking lipid panels On treatment: Recheck 4-12 weeks expect high intensity to reduce 50%+ expect moderate to reduce 30-50% Assess adherence and response

Rechecking lipid panels On treatment: Recheck 4-12 weeks expect high intensity to reduce 50%+ expect moderate to reduce 30-50% Assess adherence and response Controversial... Are we titrating to response instead of goal? Is it necessary? Guidelines say you can use your judgment on this one if you don t get expected response

What laboratory monitoring is needed on statin therapy? AST, ALT CK Creatinine

What laboratory monitoring is needed on statin therapy? AST, ALT baseline, 12 wks, annually CK baseline, then if symptoms

What laboratory monitoring is needed on statin therapy? AST, ALT baseline, 12 wks, annually CK baseline, then if symptoms Creatinine

My patient c/o muscle aches on a statin. What to do next?

Statin-induced myalgias Believe your patient! Can check CK if you suspect myopathy Options D/C and restart at lower dose (current guidelines) D/C and start low dose of a different statin Red yeast rice? Coenzyme Q10? à recent Meta-analysis negative. Consider how much you need the LDLlowering (Risk Assessment, Risk Reduction)

Do statins cause diabetes?

Do statins cause diabetes? Probably JUPITER trial Meta-analyses Effect might be small Lancet 2010 / JAMA 2011 In 1 year, ~ 1 in 1000 cases High dose NNH 500 compared with moderate dose à dose dependent Screening for DM: no different than in those without statins

Statins and DM: new stuff Decreased insulin sensitivity? Decreased insulin secretion? (Cederberg Diabetologia 2015 cohort study) Familial hypercholesterolemia: lower DM risk (Besseling JAMA 2015)

Do statins cause memory problems?

Do statins cause memory problems? Maybe Case reports FDA warning Memory loss / confusion Reversible if stop the drug

What about lifestyle measures? Yes, for everyone (of course!)

What about non-statin drugs?

What about non-statin drugs? VERY little positive RCT data for any of them Some very old data for fibrates, before the modern statin era Niacin data not beneficial (AIM-HIGH, HPS-2)

How do I discuss whether to take a statin with patients?

How do I discuss whether Language: to take a statin with patients? Match your level of concern with the patient s risk I strongly recommend This is an optional, additional way to lower risk Decision aids? (for visual learners)

How do I discuss whether Language: to take a statin with patients? Match your level of concern with the patient s risk I strongly recommend This is an optional, additional way to lower risk Decision aids? (for visual learners)

How do I discuss whether to take a statin with patients? Make it part of overall cardiovascular risk assessment: Weight, exercise, diet, blood pressure, smoking, family history... What the patient can change Optional meds to lower risk further: Aspirin, statin (is it worth it to the patient?)

Summary Many good things about the new guidelines: LDL targets never made much sense. Moving away from that is good. 4 risk categories: clinical CV disease, LDL > 190, DM, risk 7.5%

Summary But: Still seem to advocate rechecking lipids more often than is probably needed Is quite aggressive with high intensity recs Most older men will meet threshold We need the right language for shared decision making do NOT just calculate 7.5% and start a statin!

Summary But: And... Still seem to advocate rechecking lipids more Is often the treatment than is probably worth it: needed worth the potential side effects Is quite or aggressive other downsides with high such intensity as cost, recs inconvenience, Most older men etc? will meet threshold We need the right language for shared Make decision lipids making do part of overall NOT cardiovascular just calculate risk discussion 7.5% and start a statin!

In the end it s the same questions How much risk? How much treatment?

Thank you! questions